CNS Response, Inc. to Present at Acumen BioFin 9th Annual Healthcare Conference
October 29, 2007
COSTA MESA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- CNS Response, Inc. CNSO announced today that the company will be presenting at the Acumen BioFin 9th Annual Healthcare Conference to be held November 5-6, 2007 at the New York Palace Hotel. The company's Chief Executive Officer, Leonard Brandt, is scheduled to present an overview of the company and its clinical programs on Monday, November 5 at 8:50 a.m. EST in the Kennedy II (4th floor).
To access a live webcast of Mr. Brandt's presentation, please log on to CNS Response's website at http://www.cnsresponse.com approximately 30 minutes prior to the presentation in order to register and download any necessary software. The webcast will be available for 90 days at this website.
For more information on the Acumen BioFin 9th Annual Healthcare Conference please visit: http://www.rodmanandrenshaw.com/conferences.
About CNS Response
CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(SM) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.
rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG(SM) to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Contacts:
Investor Relations:
Sara Ephraim
(646) 536-7002
sephraim@theruthgroup.com
Back to News and Press